Celesa Therapeutics is set to present key clinical data on its experimental therapy deupirfenidone at the European Respiratory Society Congress in Barcelona next week. The presentations will include the trial design for the Phase 3 SURPASS-IPF study and results from a Phase 1 drug-drug interaction study.
The first presentation, scheduled for September 6 at 8:00 AM CEST, will outline the design of the SURPASS-IPF trial, which compares deupirfenidone—administered as 825 mg three times daily—to pirfenidone at 801 mg three times daily in approximately 1,100 adults with idiopathic pulmonary fibrosis. The trial’s primary endpoint is the change from baseline in absolute forced vital capacity at Week 52. The session will be led by Vincent Cottin of Louis Pradel Hospital.
On September 7 at 11:05 AM CEST, Philip Molyneaux of Imperial College London will present findings from a Phase 1 study assessing the co-administration of deupirfenidone and nintedanib. The data indicate that clinically relevant drug-drug interactions are unlikely, according to the company.
Deupirfenidone is a deuterated form of pirfenidone, a currently marketed treatment for idiopathic pulmonary fibrosis. The experimental therapy has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Commission. Prior Phase 2b trial results, published in The American Journal of Respiratory and Critical Care Medicine, showed the drug’s potential to stabilize lung function decline over at least 26 weeks.
Idiopathic pulmonary fibrosis is a progressive lung disease with a median survival of two to five years following diagnosis. There is currently no cure for the condition, underscoring the need for novel therapeutic approaches.
